European Journal of Cancer
Volume 46, Issue 8 , Pages 1413-1420 , May 2010

MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis

  • Maria Concetta Fargnoli

      Affiliations

    • Department of Dermatology, University of L’Aquila, L’Aquila, Italy
    • ,
  • Sara Gandini

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Ketty Peris

      Affiliations

    • Department of Dermatology, University of L’Aquila, L’Aquila, Italy
    • ,
  • Patrick Maisonneuve

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Sara Raimondi

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 0257489377; fax: +39 0257489922.

Received 5 November 2009 ,Revised 18 January 2010 ,Accepted 20 January 2010.

References 

  1. Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther. 2006;6:657–670
  2. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818–9828
  3. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507–1515
  4. Helsing P, Nymoen DA, Ariansen S, et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer. 2008;47:175–184
  5. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894–903
  6. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000;92:1006–1010
  7. Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst. 2004;96:785–795
  8. Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122:2753–2760
  9. Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet. 2009;18:R9–R17
  10. Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol. 2001;117:294–300
  11. Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005;97:998–1007
  12. Stratigos AJ, Dimisianos G, Nikolaou V, et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol. 2006;126:1842–1849
  13. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765–773
  14. van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001;69:774–779
  15. Chaudru V, Laud K, Avril MF, et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev. 2005;14:2384–2390
  16. Goldstein AM, Landi MT, Tsang S, et al. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005;14:2208–2212
  17. Goldstein AM, Chaudru V, Ghiorzo P, et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer. 2007;121:825–831
  18. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589–624
  19. Greenland S, Longnecker M. Methods for trend estimation from summarized dose–response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–1309
  20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  21. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  22. Debniak T, Scott R, Masojc B, et al. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer. 2006;119:2597–2602
  23. Pastorino L, Bonelli L, Ghiorzo P, et al. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res. 2008;21:700–709
  24. Chaudru V, Lo MT, Lesueur F, et al. Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Fam Cancer. 2009;8:371–377
  25. Council ML, Gardner JM, Helms C, et al. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. Exp Dermatol. 2009;18:485–487
  26. Höiom V, Tuominen R, Käller M, et al. MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res. 2009;22:196–204
  27. Peris K, Fargnoli MC, Pacifico A, et al. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. J Invest Dermatol. 2004;122:1327–1330
  28. Cuéllar F, Puig S, Kolm I, et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br J Dermatol. 2009;160:48–53
  29. Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol. 2009;129:1759–1768
  30. Ghiorzo P, Pastorino L, Pizzichetta MA, et al. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res. 2009;19:142–145
  31. Borges AL, Cuéllar F, Puig-Butillé JA, et al. CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol. 2009;161:536–541
  32. Peric B, Cerkovnik P, Novakovic S, et al. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet. 2008;9:86
  33. Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat. 2007;28:495–505
  34. Pastorino L, Cusano R, Bruno W, et al. Novel MC1R variants in Ligurian melanoma patients and controls. Hum Mutat. 2004;2:103
  35. Yang XR, Pfeiffer RM, Wheeler W, et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer. 2009;125:2912–2917

PII: S0959-8049(10)00048-1

doi: 10.1016/j.ejca.2010.01.027

European Journal of Cancer
Volume 46, Issue 8 , Pages 1413-1420 , May 2010

Article Tools

* Image Usage & Resolution